Synklino in the news
Oral presentation of late-breaking abstract at the World Transplant Congress (“WTC”) in San Francisco taking place 2-6 August 2025
The presentation will include data on the safety and feasibility of the administration of SYN002 to human kidneys during normothermic machine perfusion (NMP), as well as data on the efficacy of eliminating latently infected cells from the treated kidneys.
Synklino Submits Clinical Trial Application to UK Authorities and Prepares for Phase 1 Study of SYN002
Synklino A/S today announced the submission of its Clinical Trial Application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its first-in-human clinical trial of SYN002.
Synklino Announces Successful Outcome of Scientific Advice Meeting with MHRA in the UK
Synklino, a Danish biotech company developing drugs to treat chronic viral infections, has decided to focus the development of SYN002 on eliminating CMV in infected organs prior to transplantation (ex vivo).
Synklino focuses SYN002 development on ex-vivo organ therapy
Synklino, a Danish biotech company developing drugs to treat chronic viral infections, has decided to focus the development of SYN002 on eliminating CMV in infected organs prior to transplantation (ex vivo).